Talmadge E. King

Talmadge E. King's AcademicInfluence.com Rankings

Talmadge E. King

Philosophy

#6512

World Rank

#9557

Historical Rank

Logic

#3665

World Rank

#4859

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Talmadge E. King's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Talmadge E. King Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Talmadge E. King's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. (2011) (5108)
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors (2002) (3524)
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. (2013) (2746)
Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy (2001) (1723)
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. (2014) (1713)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials (2011) (1707)
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. (2011) (1219)
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. (2012) (1209)
Idiopathic pulmonary fibrosis (2011) (1071)
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis (2012) (861)
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. (2001) (834)
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. (2003) (692)
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. (2011) (617)
Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. (2001) (610)
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. (2004) (606)
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? (2004) (582)
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis (2005) (581)
Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. (2001) (550)
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. (2008) (485)
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial (2009) (473)
An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. (1989) (464)
High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. (2005) (449)
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease (2009) (440)
Classification and natural history of the idiopathic interstitial pneumonias. (2006) (402)
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. (2011) (391)
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. (2014) (390)
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. (2011) (383)
Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. (2012) (379)
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. (2010) (366)
Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. (1990) (360)
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? (2007) (349)
Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. (2009) (334)
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials (2016) (333)
Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. (2011) (332)
Idiopathic interstitial pneumonias: CT features. (2005) (329)
Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. (2003) (315)
Predicting survival across chronic interstitial lung disease: the ILD-GAP model. (2014) (313)
Clinical role of bronchoalveolar lavage in adults with pulmonary disease. (1990) (304)
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. (2008) (301)
Clinical advances in the diagnosis and therapy of the interstitial lung diseases. (2005) (296)
Serum surfactant proteins‐A and ‐D as biomarkers in idiopathic pulmonary fibrosis (2002) (291)
Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. (1992) (275)
Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern (2007) (273)
A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. (1986) (271)
Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. (1987) (253)
Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. (1991) (250)
AMERICAN THORACIC SOCIETY; EUROPEAN RESPIRATORY SOCIETY; AMERICAN COLLEGE OF CHEST PHYSICIANS. IDIOPATHIC PULMONARY FIBROSIS: PREVAILING AND EVOLVING HYPOTHESES ABOUT ITS PATHOGENESIS AND IMPLICATIONS FOR THERAPY (2001) (247)
Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. (2013) (244)
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? (2007) (227)
Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? (1995) (222)
Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. (2008) (221)
Rapidly progressive bronchiolitis obliterans with organizing pneumonia. (1994) (219)
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. (2005) (213)
The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. (2004) (213)
Does chronic microaspiration cause idiopathic pulmonary fibrosis? (2010) (200)
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. (2010) (200)
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. (2014) (193)
Current perspectives on the treatment of idiopathic pulmonary fibrosis. (2006) (188)
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. (2009) (186)
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. (2012) (185)
Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. (2002) (181)
Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. (1989) (177)
6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis (2013) (172)
Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. (2010) (172)
Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. (2013) (165)
Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. (1983) (163)
Respiratory Bronchiolitis-Associated Interstitial Lung Disease: Radiologic Features with Clinical and Pathologic Correlation (2002) (158)
Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. (2004) (157)
Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. (1996) (156)
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis (2012) (155)
Prevalence and prognosis of unclassifiable interstitial lung disease (2012) (155)
Hypersensitivity pneumonitis: sensitivity of high-resolution CT in a population-based study. (1992) (152)
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis (2016) (147)
Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. (1996) (147)
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference (2009) (138)
Predictors of mortality in rheumatoid arthritis‐related interstitial lung disease (2014) (134)
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. (2008) (132)
CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. (2015) (127)
Complement fragments, alveolar macrophages, and alveolitis. (1979) (125)
Acute Interstitial Pneumonitis: Case Series and Review of the Literature (2000) (124)
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. (2014) (122)
Neurofibromatosis-associated lung disease: a case series and literature review (2006) (121)
Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. (1991) (119)
Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. (2002) (119)
Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. (2013) (118)
Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. (1997) (118)
Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. The BAL Cooperative Group Steering Committee. (1991) (116)
Idiopathic pulmonary fi brosis (2011) (116)
How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine (2018) (115)
"Lifeguard lung": endemic granulomatous pneumonitis in an indoor swimming pool. (1998) (114)
Interstitial Lung Disease (2003) (109)
Correlation of structure and function in idiopathic pulmonary fibrosis. (1995) (108)
A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. (1989) (108)
How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? (1995) (107)
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials (2016) (100)
The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia (2017) (97)
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (2014) (97)
Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. (2002) (96)
Demystifying idiopathic interstitial pneumonia. (2003) (96)
American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. (2015) (96)
Challenges in pulmonary fibrosis · 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias (2007) (94)
Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. (1987) (91)
Idiopathic pulmonary fibrosis: CT and risk of death. (2014) (88)
The pleuropulmonary manifestations of the postcardiac injury syndrome. (1983) (88)
Respiratory bronchiolitis-interstitial lung disease: long-term outcome. (2007) (88)
Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. (1988) (88)
Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. (1997) (87)
Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. (1998) (86)
Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. (1997) (84)
Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma. (1991) (84)
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. (2013) (83)
Proliferative and constrictive bronchiolitis: classification and radiologic features. (1994) (83)
Imaging of pulmonary histiocytosis X. (1992) (79)
Quantification of cells recovered by bronchoalveolar lavage. Comparison of cytocentrifuge preparations with the filter method. (1988) (78)
Cryptogenic constrictive bronchiolitis. A clinicopathologic study. (1993) (77)
Chronic hypersensitivity pneumonitis: use of CT in diagnosis. (1992) (76)
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. (2015) (76)
Diffuse panbronchiolitis in the United States. (1996) (74)
International consensus statement on idiopathic pulmonary fibrosis. (2001) (73)
Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. (1990) (73)
Clinical decisions. American Board of Internal Medicine maintenance of certification program. (2010) (73)
TCR expression of activated T cell clones in the lungs of patients with pulmonary sarcoidosis. (1994) (69)
A diagnostic model for chronic hypersensitivity pneumonitis (2016) (68)
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. (2012) (67)
Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. (2003) (67)
Challenges in pulmonary fibrosis · 5: The NSIP/UIP debate (2007) (66)
Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. (1996) (65)
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. (2015) (63)
Compartmentalized immune response reflects clinical severity of beryllium disease. (1994) (59)
Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. (1995) (58)
Rheumatoid arthritis associated interstitial lung disease: a review. (2014) (56)
Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. (2007) (55)
Clonal expansion of lung V delta 1+ T cells in pulmonary sarcoidosis. (1993) (54)
Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function (2010) (54)
The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. (1991) (52)
Mortality Risk Prediction in Scleroderma‐Related Interstitial Lung Disease: The SADL Model (2017) (52)
Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. (1992) (51)
Idiopathic pulmonary fibrosis. Quantitative assessment of lung pathology. Comparison of a semiquantitative and a morphometric histopathologic scoring system. (1992) (50)
Fatigue in sarcoidosis: American versus Dutch patients. (2009) (50)
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials (2015) (50)
Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1) (2009) (48)
Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. (1990) (46)
Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. (2009) (46)
Peripheral bronchial involvement in relapsing polychondritis: demonstration by thin-section CT. (1989) (45)
Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. (1988) (44)
Lymphangioleiomyomatosis: the pathophysiology of diminished exercise capacity. (1996) (44)
Workshop on idiopathic pulmonary fibrosis in older adults. (2010) (43)
Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. (2007) (41)
Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis. (1995) (41)
Lung transplantation. Report of the ATS workshop on lung transplantation. American Thoracic Society, Medical Section of the American Lung Association. (1993) (40)
Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. (2015) (39)
Circulating immune complexes in pulmonary eosinophilic granuloma. (1979) (38)
Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation. (1993) (38)
High expression of neutral endopeptidase in idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells. (1998) (37)
The case for diversity in academic internal medicine. (2004) (37)
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. (2017) (36)
COPD: a dust-induced disease? (2005) (36)
Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. (2001) (35)
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. (2015) (33)
Smoking-related idiopathic interstitial pneumonia (2014) (30)
Cryptogenic organizing pneumonia: increased expression of interleukin-8 and fibronectin genes by alveolar macrophages. (1994) (29)
Challenges in pulmonary fibrosis: 8 · The need for an international registry for idiopathic pulmonary fibrosis (2008) (27)
Anticoagulant therapy and idiopathic pulmonary fibrosis. (2006) (25)
Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. (1993) (24)
Achieving diversity in academic internal medicine: recommendations for leaders. (2006) (24)
Pulmonary Cavitation Following Pulmonary Infarction (1985) (24)
A critical assessment of treatment options for idiopathic pulmonary fibrosis. (2004) (23)
The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study (2011) (23)
NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda. (2020) (23)
Multiple pulmonary chondromatous hamartomas. (1982) (22)
Clonal Expansion of Lung V61+ T Cells in Pulmonary Sarcoidosis (1993) (21)
Cryptogenic Organizing Pneumonia (Idiopathic Bronchiolitis Obliterans Organizing Pneumonia): An Update (1997) (20)
BOOP: an important cause of migratory pulmonary infiltrates? (1995) (19)
Bosentan for idiopathic pulmonary fibrosis. (2008) (19)
Low Prevalence of Chronic Beryllium Disease Among Workers at a Nuclear Weapons Research and Development Facility (2010) (19)
Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. (2003) (18)
Smoking and subclinical interstitial lung disease. (2011) (17)
Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation. (1987) (17)
Smooth muscle actin is expressed by air space fibroblast-like cells in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. (1991) (17)
The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF). (2009) (16)
Inequality in Health Care: Unjust, Inhumane, and Unattended! (2004) (16)
Bronchoalveolar lavage fluid neutrophils increase after corticosteroid therapy in smokers with idiopathic pulmonary fibrosis. (2015) (16)
Bronchoalveolar macrophages from patients with idiopathic pulmonary fibrosis are unable to kill facultative intracellular bacteria. (1989) (15)
Nonspecific interstitial pneumonia and systemic sclerosis. (2002) (14)
Idiopathic Interstitial Pneumonias (2006) (14)
E-Cigarette or Vaping Product Use–associated Lung Injury: Developing a Research Agenda. An NIH Workshop Report (2020) (14)
Cardiac tamponade complicating the postpericardiotomy syndrome. (1983) (14)
Treatments for idiopathic pulmonary fibrosis. (2014) (13)
Update in pulmonary medicine. (1998) (11)
Aspergillus terreus causing invasive pulmonary aspergillosis with air-crescent sign. (1986) (11)
Lessons From an Educational Never Event. (2017) (11)
Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process. (2017) (11)
Diffuse Alveolar Hemorrhage and Rare Infiltrative Disorders of the Lung (2010) (10)
Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis (2001) (10)
Cryptogenic Organizing Pneumonia. (2022) (10)
Human alveolar macrophages produce predominantly the 35-kD pro-forms of interleukin-1 alpha and interleukin-1 beta when stimulated with lipopolysaccharide. (1995) (9)
Classification of Diffuse Parenchymal Lung Disease (2007) (9)
The clinical significance of histopathologic subgroups in idiopathic interstitial pneumonia: is surgical lung biopsy essential? (2001) (8)
6-Minute Walk Test Distance (6MWD) Is A Reliable, Valid, And Responsive Outcome Measure That Predicts Mortality In Patients With IPF (2010) (8)
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro‐con perspective (2015) (8)
Erratum: Idiopathic nonspecific interstitial pneumonia: Report of an American Thoracic Society project (American Journal of Respiratory and Critical Care Medicine (2008) 177, (1338-1347)) (2008) (7)
A model of immune complex-mediated pleuropulmonary injury; evidence of deposition of circulating immune complexes in the lung. (1980) (7)
LONGITUDINAL TRENDS IN DYSPNEA IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): THE BUILD 1 STUDY (2006) (7)
The BUILD-3 Trial: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Of Bosentan In Idiopathic Pulmonary Fibrosis (2010) (7)
The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. (2015) (7)
Bilateral hilar adenopathy: an unusual presentation of renal cell carcinoma. (1982) (7)
Idiopathic Interstitial Pneumonias : CT Features 1 (2005) (6)
Lung biopsy in patients with usual interstitial pneumonia. (2001) (6)
Predictors of Mortality in Patients with Idiopathic Pulmonary Fibrosis (IPF). (2009) (6)
Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. (2004) (6)
67 – Alveolar Hemorrhage and Rare Infiltrative Diseases (2016) (6)
Pulmonary vascular involvement in pulmonary histiocytosis X. (1997) (5)
Idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia should stay separate (2008) (5)
Effect of Pirfenidone on IPF-Related Mortality Outcome Measures in Patients With Idiopathic Pulmonary Fibrosis (IPF): Pooled Data Analysis From the ASCEND and CAPACITY Trials (2015) (5)
Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis (2008) (5)
SYNDROMES THAT MIMIC IDIOPATHIC PULMONARY FIBROSIS (1992) (5)
OPEN LUNG BIOPSY IN IPF (1998) (5)
Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results (2014) (4)
Mast cell-associated basic fibroblast growth factor in the fibrotic response to environmental toxins. The Beryllium Model. (1996) (4)
Long-term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF): Integrated Analysis of Data from 4 Clinical Trials (2014) (4)
Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. (2008) (3)
A Double-Blind, Placebo-Controlled, Randomized Trial Of Combined Prednisone, Azathioprine And N-Acetylcysteine In Idiopathic Pulmonary Fibrosis (2012) (3)
Corticosteroid Therapy in the Management of Asthma (1987) (3)
Bronchiolitis obliterans (2007) (3)
Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease (2015) (2)
A Double Blind, Placebo-Controlled, Randomized Trial Of N-Acetylcysteine In Idiopathic Pulmonary Fibrosis (2014) (2)
Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. (2013) (2)
Effect Of Pirfenidone On Lung Function And Progression-free Survival (PFS) In Patients With Idiopathic Pulmonary Fibrosis (IPF): A Meta-analysis Of Three Phase 3 Studies (2010) (2)
The Effect Of Treatment With Pirfenidone On Longitudinal Change In Lung Volume In Patients With Idiopathic Pulmonary Fibrosis (IPF): A Meta-Analysis Of Outcomes In Four Randomized Controlled Clinical Trials (2011) (2)
Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) (2014) (2)
Bronchoalveolar Lavage Pepsin Levels In Acute Exacerbation Of Idiopathic Pulmonary Fibrosis (2011) (2)
Diffuse Lung Disease: Classification and Evaluation (2012) (2)
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) (2012) (2)
Waldenström's macroglobulinemia: report of a case with pulmonary involvement and recurrent pneumococcal sepsis after pneumococcal vaccination. (1984) (2)
Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY (2015) (2)
CATEGORICAL DECLINES IN PERCENT PREDICTED FORCED VITAL CAPACITY (PP-FVC) ARE ASSOCIATED WITH A GRADED RISK OF DEATH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) (2008) (2)
Pulmonary opacities and glomerulonephritis in a 15-year-old boy. (1998) (2)
6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): Confirmation of the minimal clinically important difference (MCID) (2012) (1)
Bronchoalveolar Lavage Fluid Lymphocyte Content Reflects the Histologic Alveolar Wall Inflammation of Idiopathic Pulmonary Fibrosis, Whereas Neutrophil Content Does Not (1986) (1)
Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis: recent progress and future objectives (2008) (1)
The 6 minute walk in idiopathic pulmonary fibrosis (2010) (1)
LYMPHANGIOLEIOMYOMATOSIS : DIFFERENTIAL DIAGNOSIS (1999) (1)
Extent of fibrosis by high-resolution computed tomography does not improve prediction of mortality in idiopathic pulmonary fibrosis when added to a simple clinical prediction model (2012) (1)
Understanding Nonspecific Interstitial Pneumonia: The Need for a Diagnostic Gold Standard (2009) (1)
Serum Concentrations of Surfactant Proteins A and D Predict Mortality in Patients With Idiopathic Pulmonary Fibrosis (2001) (1)
Prognostic Significance Of Surgical Lung Biopsy (SLB) In A Well-characterized Cohort Of Patients With Idiopathic Pulmonary Fibrosis (IPF) (2010) (1)
Rapidly Progressive Interstitial Lung Disease in a 58-Year-Old Man (1989) (1)
Surgical Lung Biopsy in the Diagnosis of Idiopathic NSIP: Do We Always Need It in the Initial Approach? (2009) (1)
6 Minute Walk Distance (6MWD) And Forced Vital Capacity (FVC) In Patients With Idiopathic Pulmonary Fibrosis (IPF): Similar Pattern Of Pirfenidone Response (2010) (1)
The Effect Of Treatment With Pirfenidone On Progression-Free Survival In Patients With Idiopathic Pulmonary Fibrosis (IPF): Exploratory Analysis Of Outcomes Using Novel Criteria For Disease Progression (2011) (1)
Interstitial lung diseases. Preface. (2012) (1)
Effect of Pirfenidone on All-Cause Mortality in Patients With Idiopathic Pulmonary Fibrosis (IPF): Comparison of Pooled Analysis With Meta-analysis From the ASCEND and CAPACITY Trials (2015) (0)
pulmonary and critical care pearls Pulmonary Opacities and Glomerulonephritis in a 15-Year-Old Boy * (0)
Clinical Features and Differential Diagnosis of Idiopathic Pulmonary Fibrosis (2003) (0)
Predicting Mortality in Patients with Rheumatoid Arthritis Related Interstitial Lung Disease: Expanding The GAP Model (2016) (0)
The Relationship Of Body Mass Index To Survival Time In Interstitial Lung Disease (2012) (0)
A Dust-Induced Disease? (2017) (0)
Interstitial Lung Disease, An Issue of Clinics in Chest Medicine (2012) (0)
Sarcoidosis: Clinical Management (2015) (0)
The authors reply [21] (2007) (0)
NSIP/UIP debate Challenges in pulmonary fibrosis · 5: The (2008) (0)
BOOP: a an iimportant c cause o of m migratory p pulmonary iinfiltrates? (1995) (0)
Global Assessment Of Pirfenidone-treatment Outcomes Over Time In The CAPACITY Studies Of Patients With IPF (2010) (0)
Clinical and Radiologic Diagnosis of Interstitial Infiltrates (2008) (0)
Prediction of histopathologic usual interstitial pneumonia among ILD cases with a non-diagnostic high-resolution computed tomography scan (2016) (0)
Rapid Neurologic Deterioration in a 29-Year-Old Pregnant Woman from Panama (1987) (0)
On the Differential Diagnosis of Chronic Beryllium Disease and Sarcoidosis: Reply (1990) (0)
GAP model in patients associated disease. (2017) (0)
Multiple Pulmonary Nodules in a 44-Year-Old Man (1988) (0)
Chronic Bronchiolitis in Adults (2015) (0)
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications (2012) (0)
Survival In Hypersensitivity Pneumonitis: The Clinical And Radiographic Factors Associated With Survival (2012) (0)
Diffuse parenchymal lung disease III P 3650 The decrease of surfactant protein D in bronchoalveolar lavage fluid in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia (2012) (0)
Complement Activity in Normal Rabbit Bronchoalveolar Fluid (2015) (0)
A Simple, Clinically Useful Staging System For Idiopathic Pulmonary Fibrosis (2011) (0)
Clinical Outcomes With Pirfenidone Therapy In Treatment-adherent (TA) Patients With Idiopathic Pulmonary Fibrosis (IPF) (2010) (0)
Late-breaking abstract: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) (2014) (0)
Fatigue In Patients With Sarcoidosis And Other Interstitial Lung Diseases: A Comparative Study (2010) (0)
Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. (2000) (0)
Comparative Analysis with a Neutrophii-dependent Prototype (2017) (0)
63 – Idiopathic Interstitial Pneumonias (2016) (0)
ANDREWS 'D ISEASES OF THE SKIN :C LINICAL DERMATOLOGY (2017) (0)
Circulating Autoantibodies Are Associated With Longer Survival Time In Idiopathic Pulmonary Fibrosis (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Talmadge E. King?

Talmadge E. King is affiliated with the following schools:

University of California, San Francisco